BR112023022765A2 - Proteínas de ligação ao antígeno que ligam especificamente o prame - Google Patents

Proteínas de ligação ao antígeno que ligam especificamente o prame

Info

Publication number
BR112023022765A2
BR112023022765A2 BR112023022765A BR112023022765A BR112023022765A2 BR 112023022765 A2 BR112023022765 A2 BR 112023022765A2 BR 112023022765 A BR112023022765 A BR 112023022765A BR 112023022765 A BR112023022765 A BR 112023022765A BR 112023022765 A2 BR112023022765 A2 BR 112023022765A2
Authority
BR
Brazil
Prior art keywords
antigen
binding proteins
prame
specifically bind
nucleic acids
Prior art date
Application number
BR112023022765A
Other languages
English (en)
Inventor
Claudia Wagner
Dominik Maurer
Felix Unverdorben
Florian Schworer
Frank Schwobel
Gabriele Pszolla
Heiko Schuster
Maike Jaworski
Martin Hofmann
Meike Hutt
Sebastian Bunk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of BR112023022765A2 publication Critical patent/BR112023022765A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

proteínas de ligação ao antígeno que ligam especificamente o prame. a presente invenção refere-se a proteínas de ligação ao antígeno direcionadas contra antígenos derivados da proteína prame. a invenção, em particular, fornece proteínas de ligação ao antígeno que são específicas para o antígeno prame expresso por tumor, em que o antígeno tumoral compreende ou consiste em seq id no: 50 e se encontra em um complexo com uma proteína do complexo principal de histocompatibilidade (mhc). as proteínas de ligação ao antígeno da invenção contêm, em particular, as regiões determinantes de complementaridade (cdr) de novos receptores de células t (tcr) modificados que se ligam especificamente ao referido peptídeo de prame. as proteínas de ligação ao antígeno da invenção são para uso no diagnóstico, tratamento e prevenção de doenças cancerígenas que expressam prame. além disso, são fornecidos ácidos nucleicos que codificam as proteínas de ligação ao antígeno da invenção, vetores que compreendem esses ácidos nucleicos, células recombinantes que expressam as proteínas de ligação ao antígeno e composições farmacêuticas que compreendem as proteínas de ligação ao antígeno da invenção.
BR112023022765A 2021-05-05 2022-05-04 Proteínas de ligação ao antígeno que ligam especificamente o prame BR112023022765A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184689P 2021-05-05 2021-05-05
EP21172351 2021-05-05
PCT/EP2022/062017 WO2022233956A1 (en) 2021-05-05 2022-05-04 Antigen binding proteins specifically binding prame

Publications (1)

Publication Number Publication Date
BR112023022765A2 true BR112023022765A2 (pt) 2024-01-02

Family

ID=81579586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022765A BR112023022765A2 (pt) 2021-05-05 2022-05-04 Proteínas de ligação ao antígeno que ligam especificamente o prame

Country Status (14)

Country Link
US (4) US12570760B2 (pt)
EP (1) EP4334361A1 (pt)
JP (1) JP2024518378A (pt)
KR (1) KR20240004935A (pt)
AU (1) AU2022270361A1 (pt)
BR (1) BR112023022765A2 (pt)
CA (1) CA3217738A1 (pt)
CL (1) CL2023003232A1 (pt)
CO (1) CO2023014722A2 (pt)
IL (1) IL308257A (pt)
MX (1) MX2023012902A (pt)
PE (1) PE20242343A1 (pt)
TW (1) TW202309071A (pt)
WO (1) WO2022233956A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554328B (zh) * 2023-05-11 2023-09-29 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种靶向trbv12的单链抗体、car、car-nk细胞及应用
CN118221811B (zh) * 2023-08-25 2025-05-30 立凌生物制药(苏州)有限公司 靶向prame多肽的单域抗体及其用途
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026008886A1 (en) 2024-07-05 2026-01-08 Immatics Biotechnologies Gmbh Means and methods for the quantification of target expression
CN119529098B (zh) * 2025-01-22 2025-05-30 北京可瑞生物科技有限公司 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US244A (en) 1837-06-30 Edward flint
US5204A (en) 1847-07-24 james cantelo
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
CA2156725A1 (en) 1993-02-22 1994-09-01 Warren S. Pear Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU5076301A (en) 1999-12-06 2001-07-09 Board Of Trustees Of The University Of Illinois, The High affinity tcr proteins and methods
CA2457652C (en) 2001-08-31 2012-08-07 Avidex Limited Soluble t cell receptor
WO2003029456A1 (en) 2001-10-01 2003-04-10 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
ES2327229T3 (es) 2002-11-09 2009-10-27 Immunocore Ltd. Presentacion del receptor de linfocitos t.
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
EP1714157A2 (en) 2004-01-28 2006-10-25 Immatics Biotechnologies GmbH Method for identifying and quantifying of tumour-associated peptides
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
HUE027013T2 (en) 2005-05-27 2016-10-28 Ospedale San Raffaele Srl A gene vector containing MI-RNA
AU2006259220C1 (en) 2005-06-17 2013-05-16 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
NZ564359A (en) 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
SG162818A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Multivalent entrain-and-amplify immunotherapeutics for carcinoma
EP2004837A4 (en) 2006-03-15 2009-12-23 Univ Illinois NEUTRALIZATION AGENTS FOR BACTERIAL TOXINS
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
BRPI0720342A2 (pt) 2006-10-04 2018-09-18 Janssen Pharmaceutica N.V. preparado de células apresentadoras de antígenos artificiais e seu uso em terapias celulares.
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
MX2009007571A (es) 2007-01-15 2009-07-22 Glaxosmithkline Biolog Sa Vacuna.
MX2009009589A (es) 2007-03-05 2009-09-21 Int Inst Cancer Immunology Inc Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
WO2008145139A1 (en) 2007-05-31 2008-12-04 Genmab A/S Fusion or linked proteins with extended half life
WO2009042570A2 (en) 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
US20100317546A1 (en) 2008-01-11 2010-12-16 Morphosys Ag Display Vectors and Methods and Uses Thereof
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
EP2673300B1 (en) 2011-02-11 2016-08-24 Memorial Sloan-Kettering Cancer Center Hla-restricted, peptide-specific antigen binding proteins
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CN107238706A (zh) 2011-06-28 2017-10-10 株式会社癌免疫研究所 肽癌抗原‑特异性t细胞的受体基因
WO2013041865A1 (en) 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
RU2020108070A (ru) 2012-07-27 2020-03-16 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс Конструирование t-клеточных рецепторов
US9764037B2 (en) 2012-12-06 2017-09-19 Victoria Link Limited Conjugate compounds
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CA2904369A1 (en) 2013-03-07 2014-09-12 Baylor College Of Medicine Targeting cd138 in cancer
CA2903258C (en) 2013-03-15 2019-11-26 Amgen Inc. Heterodimeric bispecific antibodies
GB201314404D0 (en) 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
MX373361B (es) 2014-03-25 2020-05-25 Boehringer Ingelheim Animal Health Usa Inc Composiciones inmunológicas que contienen histophilus somni atenuado.
IL290655B2 (en) 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
MX380612B (es) 2014-06-06 2025-03-12 2Seventy Bio Inc Composiciones de celulas t mejoradas.
RU2747457C2 (ru) 2014-07-24 2021-05-05 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
TN2017000275A1 (en) 2015-01-23 2018-10-19 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
EP4219544A1 (en) 2015-03-10 2023-08-02 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US10544392B2 (en) 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
HUE051661T2 (hu) 2015-05-18 2021-03-29 Tcr2 Therapeutics Inc Készítmények és gyógyászati felhasználások a TCR újraprogramozására fúziós fehérjék felhasználásával
HK1252998A1 (zh) * 2015-05-22 2019-06-06 Memorial Sloan-Kettering Cancer Center Prame肽专一性类t细胞受体抗体
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2017059900A1 (en) 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
WO2017070608A1 (en) 2015-10-23 2017-04-27 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
WO2017181001A1 (en) 2016-04-15 2017-10-19 Trustees Of Dartmouth College High affinity b7-h6 antibodies and antibody fragments
AU2017286310A1 (en) 2016-06-17 2018-11-15 Medigene Immunotherapies Gmbh T cell receptors and uses thereof
MX2018015937A (es) 2016-06-27 2019-05-02 Procter & Gamble Aparato y metodo para evaluar un tratamiento para la sensibilidad dental mediante producto para el cuidado bucal.
AU2017306038B2 (en) 2016-08-02 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-KRAS-G12D T cell receptors
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
US11325961B2 (en) 2016-08-05 2022-05-10 Tohoku University Natural killer cell function enhancer
CN118546961A (zh) 2016-08-26 2024-08-27 贝勒医学院 用于细胞治疗的组成型活性细胞因子受体
EP3512875A2 (en) 2016-09-15 2019-07-24 Quadrucept Bio Limited Multimers, tetramers&octamers
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
GB201617716D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc Cell
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
DE102016121899A1 (de) 2016-11-15 2018-05-17 Immatics Biotechnologies Gmbh Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
EP3615566B1 (en) 2017-04-28 2023-12-20 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
MX2019014361A (es) 2017-06-01 2020-07-27 Univ Stuttgart Dominios de ig heterodimerizantes.
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
EP3424524B1 (en) 2017-07-04 2024-12-11 CureVac SE Cancer rna-vaccine
US20190016804A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
WO2019047932A1 (zh) 2017-09-08 2019-03-14 科济生物医药（上海）有限公司 基因工程化的t细胞及应用
RU2020113627A (ru) 2017-09-20 2021-10-20 Нексиммьюн, Инк. Композиции клеток, содержащие антигенспецифические т-клетки, для адоптивной терапии
CN111133003B (zh) 2017-09-22 2024-01-12 上海药明生物技术有限公司 新型双特异性多肽复合物
TWI687227B (zh) 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
MA50613A (fr) 2017-10-03 2020-08-12 Editas Medicine Inc Molécules de liaison spécifique à l'hpv
WO2019079486A1 (en) 2017-10-18 2019-04-25 Intrexon Corporation POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS
KR20250150659A (ko) 2017-12-29 2025-10-20 메모리얼 슬로안 케터링 캔서 센터 향상된 키메라 항원 수용체 및 그의 용도
US20210041435A1 (en) 2018-01-31 2021-02-11 Tohoku University Method for regulating antigen-specific mhc expression
JP2021513347A (ja) 2018-02-11 2021-05-27 メモリアル スローン ケタリング キャンサー センター 非ｈｌａ制限ｔ細胞受容体およびその使用
CN110156889B (zh) 2018-02-14 2023-03-10 中国科学院广州生物医药与健康研究院 高亲和力HBs T细胞受体
US20210017249A1 (en) 2018-04-05 2021-01-21 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
MX2020011023A (es) 2018-04-19 2021-01-29 Baylor College Medicine Reprogramación de células t cd4 en células cd8 citotóxicas por expresión forzada de cd8ab y receptores de células t restringidos de clase 1.
JP2021522835A (ja) 2018-05-14 2021-09-02 イムノコア リミテッド 二機能性結合ポリペプチド
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
CA3106056A1 (en) 2018-07-26 2020-01-30 Ospedale Pediatrico Bambino Gesu (Opbg) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
WO2020048990A1 (en) 2018-09-04 2020-03-12 Treos Bio Zrt Peptide vaccines
WO2020057610A1 (en) 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
US20210380661A1 (en) 2018-10-16 2021-12-09 Texas Tech University System Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes
CN113226359B (zh) 2018-11-08 2024-05-24 耐克西缪恩有限公司 具有改进的表型特性的t细胞组合物
JP7571021B2 (ja) 2018-12-06 2024-10-22 グアンドン ティーシーアールキュア バイオファーマ テクノロジー カンパニー リミテッド 腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法
EP3895052A4 (en) 2018-12-14 2022-10-26 2seventy bio, Inc. DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES
CA3126064A1 (en) 2019-01-07 2020-07-16 Children's National Medical Center Improved targeted t-cell therapy for treatment of multiple myeloma
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
US12018061B2 (en) 2019-03-08 2024-06-25 St Phi Therapeutics Co., Ltd. Chimeric endocytic receptors and method of use thereof
WO2020186158A2 (en) 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
US20220153863A1 (en) 2019-03-13 2022-05-19 Hans David Staffan Ulmert Prame binding molecules and uses thereof
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
WO2020191358A1 (en) 2019-03-20 2020-09-24 Bluebird Bio, Inc. Adoptive cell therapy
AU2020261886A1 (en) 2019-04-22 2021-11-18 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
BR112021023782A2 (pt) 2019-05-27 2022-01-11 Immatics Us Inc Vetores, métodos de preparação de células t para imunoterapia, populações de células t expandidas e métodos para tratar de um paciente com câncer e para elicitar uma resposta imune
US20210040558A1 (en) 2019-07-15 2021-02-11 Neogene Therapeutics B.V. Method to isolate tcr genes
EP3999079A4 (en) 2019-07-19 2024-04-03 Memorial Sloan Kettering Cancer Center Fusion polypeptide for immunotherapy
JP2022542867A (ja) 2019-07-23 2022-10-07 ドイチェス クレブスフォルシュンクスツェントルム Ａｍｌの処置のためのポリペプチド
US20220323497A1 (en) 2019-07-24 2022-10-13 Eureka Therapeutics, Inc. Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereof
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
GB201911286D0 (en) 2019-08-07 2019-09-18 Ucl Business Plc Method
WO2021046072A1 (en) 2019-09-06 2021-03-11 Eli Lilly And Company Proteins comprising t-cell receptor constant domains
US20220396635A1 (en) 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
US20210130495A1 (en) 2019-09-27 2021-05-06 Agenus Inc. Heterodimeric proteins
US20210147929A1 (en) 2019-10-11 2021-05-20 Saint Louis University Immune receptor analysis as diagnostic assay
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
WO2021097365A2 (en) 2019-11-15 2021-05-20 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
JP2023503416A (ja) 2019-11-18 2023-01-30 バイオエヌテック エスエー Ｐｒａｍｅ ｔｃｒ受容体及びその使用
CN115210255A (zh) 2019-12-17 2022-10-18 约翰斯霍普金斯大学 靶向肿瘤抗原的mana抗体及其使用方法
CN110964122B (zh) 2019-12-24 2022-04-15 南京北恒生物科技有限公司 T细胞受体融合蛋白及其用途
JP2023515387A (ja) 2020-02-14 2023-04-13 エピバックス・インコーポレーテッド Ｃｏｖｉｄ－１９の予防、診断および治療に有用なｔ細胞エピトープクラスターおよび関連組成物
US20230082787A1 (en) 2020-02-14 2023-03-16 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class i-restricted t cell receptors against ras with g12v mutation
JP7742354B2 (ja) 2020-02-26 2025-09-19 アメリカ合衆国 Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
KR20220169488A (ko) 2020-03-16 2022-12-27 유니버시티 오브 써던 캘리포니아 신규한 항원 결합 도메인 및 이를 포함하는 합성 항원 수용체
WO2021188601A1 (en) 2020-03-16 2021-09-23 University Of Southern California Methods to prevent, ameliorate and treat complications from viral infections
WO2021211455A1 (en) 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
US20230272048A1 (en) 2020-06-10 2023-08-31 The University Of Melbourne Hiv-1 antibodies
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
CA3187259A1 (en) 2020-07-24 2022-01-27 Tscan Therapeutics, Inc. Binding proteins recognizing sars-cov-2 antigens and uses thereof
WO2022026358A1 (en) 2020-07-27 2022-02-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
US20230374140A1 (en) 2020-10-09 2023-11-23 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
WO2022083668A1 (en) 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Use of a chimeric co-stimulatory receptor for cell therapy
CN116615447A (zh) 2020-11-24 2023-08-18 上海吉倍生物技术有限公司 Ras突变体表位肽及识别ras突变体的t细胞受体
EP4263593A4 (en) 2020-12-21 2025-05-07 Zymeworks BC Inc. Stabilized TCR constructs and methods of use
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
WO2022150610A2 (en) 2021-01-08 2022-07-14 The Johns Hopkins University Sars-cov-2-specific t cell receptors and related materials and methods of use
IL305175A (en) 2021-02-19 2023-10-01 Angeles Therapeutics Inc Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
JP2024539291A (ja) 2021-10-25 2024-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経膠芽腫を治療するための方法および組成物
EP4469473A1 (en) 2022-01-24 2024-12-04 ETH Zurich Universal tcr variants for allogeneic immunotherapy
WO2023173024A2 (en) 2022-03-10 2023-09-14 The Board Of Trustees Of The Leland Stanford Junior University Treatment of coronary artery disease by reducing activity of cross-reactive t cells

Also Published As

Publication number Publication date
MX2023012902A (es) 2023-11-08
JP2024518378A (ja) 2024-05-01
KR20240004935A (ko) 2024-01-11
CA3217738A1 (en) 2022-05-04
PE20242343A1 (es) 2024-12-16
CO2023014722A2 (es) 2024-02-05
US20230357428A1 (en) 2023-11-09
US20230091330A1 (en) 2023-03-23
US20240092933A1 (en) 2024-03-21
TW202309071A (zh) 2023-03-01
IL308257A (en) 2024-01-01
AU2022270361A1 (en) 2023-11-16
US11859009B2 (en) 2024-01-02
US20220372165A1 (en) 2022-11-24
CL2023003232A1 (es) 2024-04-19
EP4334361A1 (en) 2024-03-13
US12570760B2 (en) 2026-03-10
WO2022233956A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
BR112023022765A2 (pt) Proteínas de ligação ao antígeno que ligam especificamente o prame
BR112022001923A2 (pt) Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno
JP7340127B2 (ja) がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体
CA3114451A1 (en) T cell receptor for identifying ssx2 antigen
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
CN116731156A (zh) 用于癌症免疫治疗的转染t细胞和t细胞受体
CN107921111A (zh) 用于各种癌症免疫治疗的新型肽、肽组合物和支架
JP2018509163A5 (pt)
EA037547B1 (ru) Способ активации хелперных т-клеток
US20210324034A1 (en) T cell receptor for identifying afp antigen
KR20180119605A (ko) ＨＬＡ-Ｂ５７ 개방 이형태체(open conformer)
TW201726714A (zh) 對於ｔｈ１細胞之ｃｄｃａ１抗原決定位胜肽及含此之疫苗
CA3149010A1 (en) T cell receptor for identifying ssx2 antigen short peptide
TW201106962A (en) CDC45L peptides and vaccines including the same
TW202140532A (zh) 一種辨識afp的t細胞受體及其編碼序列
NL2034657B1 (en) RCN1-derived TEIPP neoantigens and uses thereof
CN110577590A (zh) 一种识别afp抗原的tcr及其编码核酸
US10849967B2 (en) Nucleic acid molecules encoding for chimeric CSPG4 proteins and therapeutic uses thereof
MX2025013106A (es) Anticuerpos dirigidos al complejo peptidico de catepsina g del antigeno leucocitario humano
CA3233480A1 (en) Modified binding proteins and therapeutic uses thereof
CN120665183A (zh) 一种分离的特异性结合MHC/Survivin表位复合体的肿瘤特异性TCR及其用途
WO2021035446A1 (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列
EA202191411A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по b*08 пептидами и комбинациями пептидов и связанные с ними способы
EA202190555A1 (ru) Рестриктированные по в*44 пептиды для применения в иммунотерапии раковых заболеваний и связанные с ними способы
MX2023007713A (es) Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).